title: [Characterization of principal predictive biomarkers of targeted therapies in thoracic cancer].
abstract: Among non-small cell lung carcinomas, adenocarcinomas are historically the first histological sub-group for which necessary and sufficient mutations driving to cancer can be targeted by tyrosine kinase inhibitors in patients with locally advanced or metastatic forms. In 2013, targeted therapies with a marketing authorization in thoracic oncology are indicated in patients whose tumor has an EGFR-positive or ALK-positive status. Biomarkers KRAS, BRAF, HER2, PI3K, and MET can account for resistance mechanisms to these treatments and are themselves subject to development of new therapeutic inhibitors. Because the systematic detection (or in the process of being) of these biomarkers has become in the last three years an essential task for pathologists and biologists working in hospital platforms of molecular genetics of cancer supported by INCa, this article aims to describe the physiological and pathophysiological role of the main predictive biomarkers of response to targeted therapies indicated in lung adenocarcinomas.
authors.affiliation: Société Roche Diagnostics France, 2, avenue du Vercors, BP 59, 38242 Meylan cedex, France. Electronic address: frederic.eberle@roche.com.
authors.forename: F
authors.initials: F
authors.lastname: Eberlé
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy; D000077548:Anaplastic Lymphoma Kinase; D014408:Biomarkers, Tumor / Q000032:analysis*; D066246:ErbB Receptors / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D019869:Phosphatidylinositol 3-Kinases / Q000032:analysis; D011237:Predictive Value of Tests; D019859:Proto-Oncogene Proteins c-met / Q000032:analysis; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis; D013899:Thoracic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D018631:ras Proteins / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D019869:Phosphatidylinositol 3-Kinases; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D019859:Proto-Oncogene Proteins c-met; D020794:Receptor Protein-Tyrosine Kinases; D018631:ras Proteins
keywords: Biomarker; Biomarqueur; Cancer du poumon; Lung cancer; Médecine personnalisée; Personalized medicine; Signaling pathways; Targeted therapy; Thérapie ciblée; Voies de signalisation